ChemoMetec A/S (CPH: CHEMM)

Market Cap	6.52B
Revenue (ttm)	401.54M
Net Income (ttm)	143.80M
Shares Out	17.40M
EPS (ttm)	8.26
PE Ratio	45.37
Forward PE	44.33
Dividend	6.00 (1.58%)
Ex-Dividend Date	n/a

Volume	23,852
Open	378.80
Previous Close	380.20
Day's Range	374.60 - 381.80
52-Week Range	255.00 - 554.00
Beta	1.33
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 11, 2024

About ChemoMetec

ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in are areas of cell-based therapy, cancer, and stem cell research, development, and manufacturing of pharmaceuticals as well as production and quality control of animal semen and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consisten...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1997
• Employees: 167
• Stock Exchange: Nasdaq Copenhagen
• Ticker Symbol: CHEMM

Financial Performance

In 2023, ChemoMetec's revenue was 444.40 million, an increase of 3.74% compared to the previous year's 428.39 million. Earnings were 178.67 million, an increase of 12.04%.